Status:
NOT_YET_RECRUITING
iDAP Injection in the Treatment of Parkinson's Disease
Lead Sponsor:
Anhui Provincial Hospital
Conditions:
Parkinson Disease
Eligibility:
All Genders
45-75 years
Phase:
EARLY_PHASE1
Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability and preliminary efficacy that iDAP has on Parkinson's disease (PD) patients.
Detailed Description
Parkinson's disease (PD) is a common neurodegenerative disease in the middle-aged and elderly. It is the "third killer" of the middle-aged and elderly after tumors and cardiovascular and cerebrovascul...
Eligibility Criteria
Inclusion
- Ages between 45 and 75 years;
- Diagnosed to be Parkinson's disease patients according to MDS Parkinson's disease diagnostic criteria;
- Disease history 4-20 years;
- Hoehn and Yahr Stage 2-4;
- Stable dose of dopamine for more than 3 months;
- Improvement of MDS-UPDRS part III;
Exclusion
- Patients who have previously undergone brain surgery;
- Past use of stem cell therapy or participation in stem cell clinical research;
- Cognitive impairment;
- History of mental disorders;
- Patients with other serious systemic diseases;
- Past or current metastatic malignant tumors.
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2028
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06583291
Start Date
October 1 2024
End Date
October 1 2028
Last Update
September 4 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.